| __timestamp | BioCryst Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 570979 |
| Thursday, January 1, 2015 | 1896000 | 2185000 |
| Friday, January 1, 2016 | 2699000 | 4554000 |
| Sunday, January 1, 2017 | 1702000 | 3605000 |
| Monday, January 1, 2018 | 471000 | 5527000 |
| Tuesday, January 1, 2019 | 4101000 | 5234000 |
| Wednesday, January 1, 2020 | 1676000 | 6126000 |
| Friday, January 1, 2021 | 7264000 | 6784000 |
| Saturday, January 1, 2022 | 6594000 | 7592000 |
| Sunday, January 1, 2023 | 4661000 | 11450000 |
Cracking the code
In the competitive world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis compares the cost of revenue for Travere Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Travere Therapeutics consistently outpaced BioCryst, with a notable peak in 2023 where its cost of revenue reached nearly double that of BioCryst. This trend highlights Travere's aggressive growth strategy, as its costs surged by over 1,900% from 2014 to 2023. Meanwhile, BioCryst's costs increased by approximately 3,700% during the same period, reflecting its steady expansion. The data suggests that while both companies are scaling, Travere's rapid increase in costs may indicate a more aggressive market penetration strategy. Investors should consider these trends when evaluating the financial health and strategic direction of these biotech firms.
Pfizer Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Pfizer Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Sanofi and Travere Therapeutics, Inc.'s Expenses
Neurocrine Biosciences, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Viatris Inc. vs Travere Therapeutics, Inc.
Cost Insights: Breaking Down Catalent, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Grifols, S.A. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Analyzing Cost of Revenue: MorphoSys AG and Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.
Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
BioCryst Pharmaceuticals, Inc. vs Evotec SE: Efficiency in Cost of Revenue Explored